Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes

被引：0
|
作者：
Kristoffer Sand
Jakob Theorell
Øystein Bruserud
Yenan T. Bryceson
Astrid Olsnes Kittang
机构：
[1] University of Bergen,Department of Clinical Science
[2] Karolinska University Hospital Huddinge,Center for Infectious Medicine, Department of Medicine, Karolinska Institutet
[3] Haukeland University Hospital,Division for Hematology, Department of Medicine
来源：
Cancer Immunology, Immunotherapy | 2016年 / 65卷
关键词：
Myelodysplastic syndromes; Cytotoxic T lymphocytes; CD57; CX3CR1; Granzyme B; Adhesion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1135 / 1147
页数：12
相关论文
共 50 条
  • [41] Part 5: Myelodysplastic syndromes-Treatment of high-risk disease
    Meira Magalhaes, Silvia Maria
    Lopes Ferrari Chauffaille, Maria de Lourdes
    Rodrigues Pereira Velloso, Elvira Deolinda
    Buzzini, Renata
    Bernardo, Wanderley Marques
    [J]. HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2018, 40 (03) : 278 - 282
  • [42] The Different Immunoregulatory Functions of Mesenchymal Stem Cells in Patients with Low-Risk or High-Risk Myelodysplastic Syndromes
    Zhao, Zhigang
    Wang, Zhenling
    Li, Qiubai
    Li, Weiming
    You, Yong
    Zou, Ping
    [J]. PLOS ONE, 2012, 7 (09):
  • [43] Desire for Prognostic Information and Quality of Life Outcomes in Patients With High-Risk Myelodysplastic Syndromes. (FR)
    Efficace, Fabio
    Gaidano, Gianluca
    Breccia, Massimo
    Caocci, Giovanni
    Voso, Maria T.
    Sprangers, Mirjam
    Criscuolo, Marianna
    Lunghi, Monia
    Tucci, Anna Adi
    Beyne-Rauzy, Odile
    Buccisano, Francesco
    Deschler, Barbara
    Platzbecker, Uwe
    [J]. QUALITY OF LIFE RESEARCH, 2012, 20 : 45 - 46
  • [44] Elevated serum TNF-α concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes
    Alexandrakis, M
    Coulocheri, S
    Xylouri, I
    Ganotakis, E
    Eliakis, P
    Karkavitsas, N
    Eliopoulos, GD
    [J]. HAEMATOLOGIA, 1998, 29 (01) : 13 - 24
  • [45] A phase I study of AMV564 in patients with intermediate or high-risk myelodysplastic syndromes.
    Garcia-Manero, Guillermo
    Jacoby, Meagan
    Sallman, David Andrew
    Han, Tae
    Guenot, Jeanmarie
    Feldman, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities
    Hiddemann, W
    Jahns-Streubel, G
    Verbeek, W
    Wörmann, B
    Haase, D
    Schoch, C
    [J]. LEUKEMIA RESEARCH, 1998, 22 : S23 - S26
  • [47] GLOBAL DNA METHYLATION PREDICTS THE RESPONSIVENESS TO AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Poloni, A.
    Goteri, G.
    Zizzi, A.
    Serrani, F.
    Costantini, B.
    Trappolini, S.
    Mariani, M.
    Leoni, P.
    [J]. HAEMATOLOGICA, 2012, 97 : 133 - 133
  • [48] Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes
    Fenaux, Pierre
    Ades, Lionel
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S7 - S11
  • [49] HEMATOLOGIC RESPONSE TO AN ALTERNATIVE DOSING SCHEDULE OF AZACITIDINE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES
    Finelli, C.
    Clissa, C.
    y Follo, M.
    Curti, A.
    Paolini, S.
    Papayannidis, C.
    Testoni, N.
    Ottaviani, E.
    Parisi, S.
    Martinelli, G.
    Cocco, L.
    Baccarani, M.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 560 - 560
  • [50] Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience
    Improta, S.
    Gagliardi, A.
    Villa, M. R.
    Della Cioppa, P.
    Esposito, M.
    Izzo, G. Nitrato
    Mastrullo, L.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S152 - S152
12345